Week in Review: CANbridge Licenses LogicBio's Adeno-Associated Virus for Gene Therapies in $591 Million Deal

Deals and Financings   Beijing 's CANbridge Pharma in-licensed LogicBio’s adeno-associated virus to use with gene therapy candidates for rare diseases in a $581 million deal; In a second agreement, CANbridge announced a $120 million deal for Greater China rights to develop maralixibat for rare inherited childhood liver diseases; VivaVision Biotech of  Shanghai  completed a $46 million Series D financing for novel chronic ocular or dermal inflammatory disease candidates; Adcentrx. a Shanghai-San Diego startup, closed a $50 million Series A round to develop next-gen ADC candidates for cancer and other serious diseases; Tianhong Shengjie, a  Suzhou  company developing medical devices for venous diseases, completed a $12 million Series B financing; Sirnaomics ( Suzhou ) out-licensed Greater China rights for its anti-influenza siRNA candidate to Walvax of Kunming for a $6.4 million upfront payment;  CRO/CMO News   dMed Global, a  Shanghai  clinical CRO, merged with Clinipace, a  North Carolina  clinical CRO, to offer cross-border clinical contract research services; Guangzhou Link Health Pharma and Australia 's George Clinical will form a  China  clinical CRO JV to conduct trials for Link Health's in-licensed portfolio;  Trials and Approvals   Nanjing Legend Biotech filed for EU approval of its BCMA CAR-T candidate in patients with multiple myeloma; Suzhou 's CStone Pharma reported China 's NMPA accepted its pralsetinib NDA for review to treat RET-altered thyroid cancer; Shanghai Fosun Pharma started a China Phase III trial of its next-gen long-lasting Botox drug for aesthetic and cervical dystonia uses; Shanghai 's I-Mab reported positive topline data from a Phase II trial of a selective IL-6 inhibitor in patients with ulcerative colitis.   Stock Symbols: (NSDQ: LEGN) (HK: 2616) (SHA: 600196; HK: 02196) (NSDQ: IMAB) Share this with colleagues: // //